ResMed (RMD) reported that it has completed its acquisition of Propeller Health, a digital therapeutics company providing connected health solutions for people living with chronic obstructive pulmonary disease (COPD) and asthma. The addition of Propeller’s business is expected to have a dilutive impact on ResMed’s non-GAAP earnings per share in the range of $0.01 to $0.02 per quarter during the remainder of Fiscal Year 2019
ResMed poised to provide broader suite of sol. for COPD treatment
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$38.11 |
Change
-0.240(0.63%) |
Mkt cap ! $22.38B | |||
| Open | High | Low | Value | Volume |
| $38.50 | $38.57 | $37.66 | $49.01M | 1.287M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6322 | $38.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $38.12 | 8095 | 3 |
View Market Depth
| Last trade - 16.10pm 27/11/2024 (20 minute delay) ? |
| RMD (ASX) Chart |
